Biogen Licenses InnoCare’s Orelabrutinib to Strengthen Multiple Sclerosis Presence

By Debadrita Paul

Pharma Deals Review: Vol 2021 Issue 8 (Table of Contents)

Published: 10 Aug-2021

DOI: 10.3833/pdr.v2021.i8.2631     ISSN: 1756-7874

Section: Licensing



Continuing its efforts in the multiple sclerosis (MS) treatment space, Biogen has agreed to in-license InnoCare’s orelabrutinib for multiple sclerosis (MS) and certain autoimmune diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details